Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib plus P-Gemox for newly diagnosed aggressive NK cell leukemia
ChiCTR2400086092Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in aggressive NK-cell leukemia (ANKL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Overall survival and Safety. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
03
Conditions
aggressive NK-cell leukemia (ANKL)
Beyond the preview
Go deeper on ChiCTR2400086092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086092.